ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TSL Thinksmart Limited

28.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Thinksmart Limited LSE:TSL London Ordinary Share AU000XINEAE8 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 28.50 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Thinksmart Share Discussion Threads

Showing 1 to 22 of 975 messages
Chat Pages: Latest  3  2  1
DateSubjectAuthorDiscuss
22/2/2004
22:43
phoenxbird glad I caught yo the other night. The Intercast has two entry levels. The method you logged in at was superjava designed fot dialup users the other method is a Hotcom download meant for broadband users.
Very interesting day the next as the AFG AFD Ceo came on and there were 135 users on at once all with the potential to badger the CEO. His pitch was good and did no end of good to the share price. Pfofit takers probably brought it downn. Still holding at least for the short term.

whitebicycle
17/2/2004
13:56
Many thanks.
phoenixbird
17/2/2004
13:40
The chat button on the toolbar bar above. A hybrid chatroom that has presenters hosting the room during the day. Guests can text in or use a mike if available. Had a few CEOs using for a presentation followed by a Qand A session. Generally populated by small investors, a few traders and the oddball that comes on makes a few noises and leaves.
Require a software download.

whitebicycle
17/2/2004
12:46
Hi Whitebike. Excuse my ignorance but what exactly is Intercast?
phoenixbird
17/2/2004
10:45
Checked out the site yesterday phoenixbird, quite impressed as I had bought blind on friday. Discussed on the Intercast and Patrica went through the fundamentals, no surprises. Told by source it was good for 160p, looking at it now I think its good for a bit more.
I'll do more research on Permacol, thanks for the reply,
Regards,
WhiteBike.

whitebicycle
17/2/2004
10:17
As you will have noted, very few purchases today have pushed the price up 11.5p (as at 10:15am). Tons of upside on this one due to shortage of stock. Check out the TSL website re: product portfolio. The Permacol product has huge potential and has been taken up by CR Bard (a $6bn company in the US).
phoenixbird
17/2/2004
10:11
Thanks phoenixbird, entered it for the Intercast weekly comp, out in front at the moment, could win me a months worth of Level 2.
whitebicycle
16/2/2004
22:23
There is a shortage of stock, shares are tightly held. Two purchases of 25,000 each on Friday afternoon (delayed transactions)have pushed up the price today.
phoenixbird
16/2/2004
16:05
Bought these Friday on a tip.Now moving up on nil volume, is news expected?
whitebicycle
06/2/2004
14:37
Movement over last two days...
muscapharoah
11/11/2003
15:43
Movement has started though a bit late, however worth watching...
Parv

parvez
10/10/2003
12:31
FAirly positive write up in Shares mag although 'Only' a HOLD recommendation. Says that Zimmer deal was largely ignored by the markets and suggests that a new deal with Bard may be in the offing
ok,yah
09/10/2003
11:47
Up today. There is a reasonable amount of interest in comparison with recent months. You only have to look at the chart to see the recent surge in the share price. Its a stock for the longer term not for short term traders
ok,yah
08/10/2003
10:03
Not much interest in this stock at all at the moment. Share price hardly moves.
muscapharoah
07/10/2003
08:48
Bit of background info:

PermacolTM
Porcine Collagen

AN INNOVATION IN BODY REPAIR

Just like machinery, our bodies need repairing from time to time as the result of accident, illness, body defect, or simply as we get older. To carry out such corrective operations, e.g. repair of hernia or waterworks, accident damage particularly on the face, breast reconstruction, removal of debilitating scarring after injury or previous surgery, etc., surgeons need materials which may be used safely inside the body. They must not be rejected, must be non-toxic, effective, and last a long time.

Materials currently available to surgeons include synthetic products made from silicon or polymers, mesh, Teflon, and natural products taken mostly from human or animal tissue such as collagen, skin grafts, and fat. Unfortunately, synthetic products by their very nature may lead to irritation or rejection, and never become fully integrated inside the body. Given the choice, surgeons largely prefer to use the natural (biological) products, but they are broken down by the body's processes, so do not last long.

PermacolTM - an innovation in surgical body repair

Developed by UK scientists over the past 20 years from pigskin (which has a structure very close to human tissue), PermacolTM is the world's first biological surgical implant material which provides the answers to surgeons' needs. It is safe, non-toxic, and is accepted by the body - indeed, it allows ingrowth by tissue cells and blood vessels. It is not broken down and therefore enables the surgeon to provide a permanent, strong repair.

In flat sheet format PermacolTM is very strong yet flexible, and may easily be sutured or stapled, e.g. in a hernia repair.

PermacolTM has been pioneered by Tissue Science Laboratories, a new all-British biopharmaceutical company dedicated to the research and development of natural products for the repair and reconstruction of human tissue

ok,yah
30/9/2003
13:01
Any views about this stock?
muscapharoah
30/9/2003
07:27
This should move quickly on a bit of buying.
ok,yah
30/9/2003
06:37
(Warsaw, Indiana and Aldershot, UK) -- Zimmer Holdings, Inc. (NYSE:ZMH) and
Tissue Science Laboratories (LSE:TSL) today announced that they have entered
into an exclusive, multi-year worldwide agreement to distribute an innovative,
nonresorbable biological patch for the repair of rotator cuff injuries in the
shoulder. The product, PermacolTM Surgical Implant, was developed and is
manufactured by Tissue Science Laboratories plc

Todays results sound very upbeat as well

ok,yah
24/9/2003
14:27
Not much discussion on this thread nowadays but I think this might be due for a rise Panmure rate this as a strong buy with forecasts for 2004 for earnings per share of 14.01p vs current share price of 86p. Has been ticking up slightly of late.

The share has barely moved for a long time after almost halving in the bear markets yet the company remains upbeat and says it will not need funding again before profitability.

ok,yah
21/3/2002
10:43
up 1p, i wonder if this will be start of another move north, seems good so far anyway... watching
oneliner
11/3/2002
08:34
RNS Number:7043S
Tissue Science Laboratories PLC
11 March 2002

11 March 2002



Preliminary Results for the year ended 31 December 2001

Tissue Science Laboratories plc ('TSL'), the medical devices company
specialising in human tissue replacement and repair products derived from
porcine dermis, today announces its Preliminary Results for the year ended 31
December 2001.

Financial highlights

- Successful flotation in December 2001 on the Alternative Investment
Market which raised £10 million, before expenses

- Turnover increased to £1.7 million (8 months to 31 December 2000:
£0.1 million), primarily as a result of sales of PermacolTM Surgical
Implant commencing in the US in April 2001

- Loss for the year of £3.4 million (8 months to 31 December 2000: £1.4
million) in line with expectations

- Net funds at the year end of £8.4 million (2000: £0.1 million)


Operational highlights

- Positive progress being made with CR Bard Inc. in the urology and
gynaecology market in the US and Europe, with sales of PermacolTM
Surgical Implant progressing well

- Appointment of Mike Waller as VP Sales and Marketing, for North
America and the strengthening of the Sales and Marketing team for
Europe

- In January 2002, FDA approval received for PermacolTM Surgical
Implant for Head and Neck applications; the Company is actively
seeking a distribution partner in this area

- A new manufacturing facility is being built to meet future capacity
requirements and to bring current sub-contract facilities in-house.
Completion expected mid 2002.

- Commercial launch of PermacolTM Injectable (Urethral Bulking Agent)
in Europe is expected in the second half of 2002.

Commenting on the results, Martin Hunt, CEO of TSL, said:

"Our strategy remains focused on the commercialisation of our technology and the
development of products which address the opportunities identified in our target
markets. There is still much to achieve, but we are looking forward to meeting
the challenges ahead. Current trading is in line with expectations and we
remain confident that we have laid the foundations of a first class medical
devices company."

-Ends-

Enquiries:
TSL plc Tel: 01252 333 002
Martin Hunt, Chief Executive
Financial Dynamics Tel: 020 7831 3113
Melanie Toyne-Sewell / Fiona Noblet


REVIEW FOR THE YEAR

INTRODUCTION

These are the first results for TSL plc as a public company after our successful
flotation on the Alternative Investment Market ('AIM') in December 2001, when
conditions in the financial markets were difficult. Against this background, the
market responded positively to our offering and we were able to raise the funds
required to finance our future development. We will be investing the proceeds in
human clinical studies for our development products, a new manufacturing
facility to support our planned requirements and commercial expansion in both US
and Europe.

FINANCIAL PERFORMANCE

At flotation, the Company raised £10 million, before expenses, via a placing
which valued the Company at £32.3 million. Additional fund raising activities
during the year included two share offers in March and September which raised
£1.7 million in total, and a £2.0 million bridging facility in the form of a
convertible redeemable loan note. Since flotation, £1.2 million of the loan
note has been repaid with the remaining £0.8 million converted into ordinary
shares.

Turnover for the year was significantly increased at £1.7 million (8 months
ended 31 December 2000: £0.1 million) following the launch of PelvicolTM by CR
Bard Inc. ('Bard') in the US in April 2001. The loss for the year after
exceptional items of £3.4 million (8 months ended 31 December 2000: £1.4
million) was in line with expectations and reflects increased product
development expenditure and infrastructure costs in manufacturing, marketing and
administration. The exceptional operating charges relate to payments of
£130,000 made to secure the assignment to the Company of patent rights over our
core technology and £54,241 in respect of flotation costs not chargeable to the
share premium account. In addition, £238,653 of exceptional costs in relation to
the £2.0 million bridging loan have been reported within interest payable and
similar charges.

The basic loss per share of 25.6p compares with 13.8p for the 8 months to 31
December 2000. The balance sheet at the year end showed a solid cash position
of £8.7 million (net funds of £8.4 million) as a result of the fund raising at
flotation.

OPERATIONAL REVIEW

The market

The market opportunity for our existing and development products is significant.
The soft tissue implant market is c. $1.0 billion worldwide and is growing
rapidly, partly as a result of the demand by surgeons to use new materials that
offer real benefits over what is currently available. Concerns over the use of
existing bovine and cadaver-sourced products on safety grounds also offer an
opportunity for our technology. In addition, during 2002, we expect changes to
be made by the European regulatory authorities in the way bovine-sourced
materials are regulated to reflect their risk profile.

Within the total soft tissue implant market, we are targeting for 2002 a number
of sectors with PermacolTM Surgical Implant, namely:

- Urology/Gynaecology - immediate market potential $165m (Figures for the
US market only)

- Head & Neck - immediate target market in excess of $60m (Figures for the
US market only)

- General surgery - market potential $120m (Figures for the US market only)

Sales and marketing

Sales strategy

Our strategy for PermacolTM Surgical Implant is to operate directly in the UK,
and through distribution partners in our other target markets in the US and
Europe. Our first such partnership is with Bard in the field of urology and
gynaecology. PelvicolO (the Bard trade name) was launched in Europe in April
2000 and in the US in April 2001. Bard is a leading urology company with the
critical mass and reputation in the field to achieve rapid market penetration,
and the partnership is progressing well.

In the US, in parallel with our strategy in urology, we are targeting other
specific applications of our technology into market segments where we can
differentiate the product from competitors. Specifically, we are focusing on
applications in the area of head and neck surgery and hernia repair where the
characteristics of the product are especially appropriate. To access these
sectors we intend to take a diversified approach to distribution. For head and
neck surgery, we are currently seeking a distribution partner with an
established market presence. In order to target specific areas of general
surgery, such as the hernia repair market, we intend to use commission-only
sales personnel to commence selling the product in the second half of 2002.

In Continental Europe, we are actively seeking national distributors with
existing, complementary product ranges to promote our technology across a
variety of surgical applications referred to above, excluding gynaecology /
urology applications which are covered by the Bard partnership. In the UK, we
have our own sales force which we have recently increased to five. This means
that we now have national coverage for the first time.

Access to surgeons who specialise in each of the surgical applications we are
targeting, is essential to the selling process. Introduction of a product such
as PermacolTM Surgical Implant requires the sales team to identify opinion
leaders and use their acceptance of the product to influence other potential
users. Through Bard and our own sales team, we are developing support programmes
to enhance our market penetration using surgeons who have converted to routine
usage of PermacolTM and we will continue to build on this approach as we enter
the new sectors we have targeted.

Sales and marketing infrastructure

To support our commercial expansion, we have an office in the UK. Since
flotation, we have also opened a small sales office in Atlanta, USA - this
office is now up and running and will provide a base for the expansion of sales
efforts in that territory.

Since the year end, we have also strengthened the sales team. In January 2002,
Mike Waller was appointed Vice President Sales & Marketing, North America. He
joined TSL from Bard Urological Division where he was Senior Marketing Manager
with responsibility for the launch of PelvicolO in the US. Mike was instrumental
in influencing key opinion leaders to adopt PelvicolO in the North American
urological market. Other senior appointments made from within TSL include, John
Brannigan Sales and Marketing Director for Europe, and Rob Sawyer who has been
appointed Head of Marketing for Europe.

Current trading

In 2001, we experienced strong growth in the US and Europe; the characteristics
of the product, have been well received by the market, in particular, in the US
market since its launch in April 2001. Approximately 76% of total sales were
generated in the US.

Since the year end, we have continued to see our US and European sales growth
continue according to plan, both through Bard and via our own team in the UK.
Trading is progressing in line with expectations.

Manufacturing

To date, manufacturing operations have been carried out via subcontract
arrangements under the direct supervision of TSL personnel. We are investing
£1.5 million of the proceeds of the flotation in our own manufacturing facility,
located in premises immediately adjoining those of our current subcontract
manufacturer. This project is now well underway and once complete, this
development will enable us to bring our manufacturing operations in-house. As
part of this process, we have agreed the transfer of certain personnel from our
current subcontractor which will mean that expertise and know-how that has been
developed to date will not be lost to the Company. This project is planned for
completion in the second half of 2002.

Peer recognition

TSL is working with surgeons across a number of disciplines to publish papers
and write up case studies on the use of PermacolTM Surgical Implant in human
tissue repair. Recent examples include product usage in abdominal repair,
paediatric applications, maxillofacial procedures and pelvic floor repairs. We
are also working with a number of academic institutions to further develop the
applications of our core technology. We will update shareholders on progress
going forward.

Regulatory affairs

Our regulatory workload remains high as a result of our product development
activities and planned manufacturing facility. This includes submissions to the
US Food and Drug Administration ('FDA') for our injectable product being
developed to treat female stress incontinence and preparatory work for the same
regulatory pathway for the cosmetic reconstruction injection and submissions to
the European authorities for the latter product. In addition, our new
manufacturing facility must be validated and approved to meet US and European
standards. With this in mind, we have recruited an experienced Regulatory
Affairs manager from within the healthcare industry. We will retain our
European and US consultants for strategic advice, but we will bring the majority
of the regulatory work in-house. This will increase our efficiency and reduce
the overall cost of the regulatory function.

New product development

The current focus for development is to produce injectable variants of our core
technology.

PermacolTM Surgical Implant (Urethral Bulking Agent)

We are targeting the female stress incontinence market, an area of significant
unmet need with an estimated 7.7 million sufferers in the US. Our product is
currently undergoing human clinical studies in Europe. Although already
possessing a CE mark allowing us to sell the product in Europe, we require
Pre-Marketing Approval (PMA) in order to launch in the US in 2004. These
clinical evaluations are a key element of our submission to the FDA.

In addition, we are conducting evaluations of the product to provide marketing
data to support its commercial launch in Europe in the second half of 2002. The
next stage of development activity for this product is to move from pilot scale
to commercial scale manufacture.

PermacolTM Surgical Implant Injectable (CR)

This version of our injectable product which is being designed for use in
cosmetic reconstruction and facial augmentation is at an earlier stage of
development. As with the urethral bulking agent, the regulatory pathway for the
US market is a PMA and launch is not anticipated before 2004. The market for
cosmetic augmentation is substantial - in the US, it has a potential value of
$540 million, and it is liable to grow rapidly as the wealthy western population
ages.

Board appointments

During the year (prior to the flotation), a number of key appointments were
made. John Hamer joined the Company in January 2000 and was appointed as
Director of Scientific Affairs in May 2001. David Jennings stepped up to the
Board as Finance Director in September 2001. David Lindop was appointed as a
non-executive director in November 2001. Currently, the Board consists of three
executive directors, three non-executive directors and a non-executive chairman.

Outlook

Our strategy remains focused on the commercialisation of our technology and the
development of products which address the opportunities identified in our target
markets.

During 2002, we are seeking to open further sales and distribution channels with
respect to new applications and geographical locations. We will also continue
to invest in building the management team that will be able to deliver rapid
growth and a sustainable increase in value to shareholders. There is still much
to achieve, but we are looking forward to meeting the challenges ahead. Current
trading is in line with expectations, and we remain confident that we have laid
the foundations of a first class medical devices company.


Patrick Paul Martin Hunt
Chairman Chief Executive



Tissue Science Laboratories plc
Consolidated Profit & Loss Account for the Year Ended 31 December 2001


Pro-forma
Year ended Year ended 8 months ended
31 December 31 December 31 December
2001 2000 2000
Note (Audited) (Unaudited) (Audited,
restated)
£000s £000s £000s
______ ______ ______
TURNOVER 4 1,706 432 112
Cost of sales (1,512) (415) (313)

______ ______ ______
Gross profit / (loss) 194 17 (201)

Selling & distribution costs (302) (135) (80)

Administrative expenses
Research and development costs (1,293) (795) (616)
Other administrative expenses (1,522) (767) (568)
Exceptional administrative expenses 5 (184) - -
______ ______ ______
(2,999) (1,562) (1,184)
______ ______ ______
Operating loss (3,107) (1,680) (1,465)

Interest receivable 28 39 35
Interest payable and similar charges
Bank and finance lease interest (54) (3) (1)
Exceptional finance costs 5 (239) - -
______ ______ ______
(293) (3) (1)
______ ______ ______
RETAINED LOSS ON ORDINARY ACTIVITIES BEFORE AND
AFTER TAXATION (3,372) (1,644) (1,431)

______ ______ ______

Basic loss per ordinary shares 6 25.6p N/a 13.8p
Diluted loss per ordinary share 6 25.7p N/a 13.9p


All amounts relate to continuing operations

There were no recognised gains and losses for the current or preceding period
other than those included in the profit and loss account.

There is no difference between the retained loss on ordinary activities before
or after taxation for the period stated above and their historical cost
equivalents.

No dividend has been paid or is payable in either the current or prior periods.

The prior year adjustment is disclosed in note 2.

An unaudited pro-forma profit and loss account has been included for the year
ended 31 December 2000 for the purposes of comparison. This pro-forma
information is based on management accounts, which have not been subject to
audit.


Tissue Science Laboratories plc
Consolidated Balance Sheet as at 31 December 2001


31 December 31 December
2001 2000
(Audited) (Audited, restated)
£000s £000s
______ ______
FIXED ASSETS
Tangible assets 857 530

CURRENT ASSETS
Stocks 172 57
Debtors 875 159
Cash at bank and in hand 8,711 160
______ ______
9,758 376
______ ______
CREDITORS: amounts falling due within one year (1,925) (521)
______ ______
NET CURRENT ASSETS/(LIABILITIES) 7,833 (145)
______ ______
TOTAL ASSETS LESS CURRENT LIABILITIES 8,690 386
______ ______
CREDITORS: amounts falling due after more than
one year (176) (16)
______ ______
NET ASSETS 8,514 369
______ ______
CAPITAL AND RESERVES
Called up share capital 2,212 1,060
Share premium account 12,477 2,157
Shares to be issued 46 -
Merger reserve 545 545
Profit & loss account (6,766) (3,393)
______ ______
EQUITY SHAREHOLDERS' FUNDS 8,514 369
______ ______


Tissue Science Laboratories plc
Consolidated Cash Flow Statement for the year ended 31 December 2001

Year ended 8 months ended
31 December 31 December
2001 2000
Note £000s £000s
______ ______
Net cash outflow from operating activities 7 (2,274) (1,220)
______ ______
Returns on investment and servicing of finance 8 (265) 33
______ ______
Capital expenditure and financial investment 8 (626) (290)
______ ______
Cash outflow before use of liquid resources and
financing (3,165) (1,477)
______ ______
Financing

Net cash inflow/(outflow) from financing 8 11,720 (3)
______ ______
Increase/(decrease) in cash in the year 8,555 (1,480)
______ ______
RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS
Increase/(decrease) in cash in the year 8,555 (1,480)
______ ______
Cash (inflow)/outflow from movement in debt and
lease financing (249) 3
Change in net funds / (debt) resulting from cash flows 8,306 (1,477)
New finance leases - (28)
Currency translation difference (5) 4
______ ______
Movement in net funds / (debt) in the year 8,301 (1,501)
______ ______
Net funds brought forward 134 1,635
______ ______
Net funds carried forward 8,435 134
______ ______



Tissue Science Laboratories plc
Statement of Total Recognised Gains and Losses
For the year ended 31 December 2001


Year ended 8 months ended
31 December 31 December
2001 2000
Note (Audited) (Audited, Restated)
£000s £000s
______ ______
Loss for the financial year (3,372) (1,431)
Total recognised gains and losses in the period (3,372) (1,431)
Prior period adjustment 2 (1,039)
______
Total recognised gains and losses
since the last annual report (4,411)
______



Notes

1 ACCOUNTING POLICIES AND BASIS OF PREPARATION

The financial information set out in this announcement does not constitute the
Company's statutory accounts for the year ended 31 December 2001 or for the
eight months ended 31 December 2000, but is derived from those accounts.
Statutory accounts for the eight months ended 31 December 2000 have been
delivered to the Registrar of Companies and those for the year ended 31 December
2001 will be delivered following the Company's annual general meeting. The
auditors have reported on those accounts; their reports were unqualified and did
not contain statements under s237(2) of (3) Companies Act 1985.

The financial statements for the year ended 31 December 2001 have been prepared
after taking into account FRS 18 Accounting Policies for the first time.

The adoption of FRS 18 has not had a material impact on the Company's financial
statements.

The accounting policies adopted are consistent with those adopted in the
previous period, except for the restatement detailed in note 2.

2 RESTATEMENT OF COMPARATIVES AND PRIOR YEAR ADJUSTMENT

The following changes have resulted in the restatement of comparatives and a
prior year adjustment.

The adoption of merger accounting on consolidation has resulted in the creation
of a merger reserve, the write-off of purchased goodwill has resulted in an
increase of retained losses brought forward and the more appropriate assessment
of risks attached to leases which has resulted in the capitalisation of leases
previously treated as operating leases.

As a result of the changes in policy, the comparatives have been restated as
follows:

Consolidated Balance Sheet
Retained
losses
Intangible Tangible Merger brought
fixed assets fixed assets Creditors reserve forward
£000s £000s £000s £000s £000s
______ ______ ______ ______ ______
31 December 2000 as previously
reported 494 504 511 - (2,353)
Merger accounting and goodwill
write-off (494) - - 545 (1,039)
Capitalisation of leases - 26 26 - -
______ ______ ______ ______ ______
31 December 2000 restated - 530 537 545 (3,392)
______ ______ ______ ______ ______


Operating Interest Loss for the

oneliner
06/2/2002
00:46
Could be interesting, recently tipped, not sure if there's froth in the price or not but I have had a punt. They have some approvals, check RNS via Quotes page.

Do your own research please, feel free to discuss below pros/cons.

oneliner
Chat Pages: Latest  3  2  1

Your Recent History

Delayed Upgrade Clock